


This listing of the claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1-14. (Cancelled)

15. (Currently Amended) A solid phase bound organic conjugate represented by formula (I)



wherein the sphere is a solid phase support;

C is a methylene group carbon atom;

R<sub>4</sub> and R<sub>5</sub> are independently selected from the group consisting of H, aliphatic substituents, aromatic substituents, RO, RS and (R)<sub>2</sub>N, wherein R is an aliphatic or aryl group;

L is a linker or a single bond; and

each of R<sub>1</sub> and R<sub>2</sub> is independently a metal coordinating group, a non-coordinating organic group, a metal coordinating group derivatized with a biologically active molecule, or a non-coordinating organic group derivatized with a biologically active molecule.

16. (Previously Presented) A solid phase bound organic conjugate according to claim 15, wherein the biologically active molecule is selected from the group consisting of amino acids, steroids, peptides, proteins, carbohydrates, polysaccharides, oligosaccharides, nucleosides, nucleotides, oligonucleotides, polynucleotides, lipids, and pharmaceutically active small molecules.


17. (Previously Presented) A solid phase bound organic conjugate according to claim 15, wherein the solid phase support is a polyethylene glycol resin or a hybrid of polyethylene glycol and polystyrene.

18-19. (Cancelled).

20. (Currently Amended) A kit for the preparation of a diagnostic or therapeutic pharmaceutical composition, the kit comprising:

a container; and

a molecule of solid phase bound organic conjugate in said container represented by formula (I),



wherein the sphere is a solid phase;

C is a methylene-group carbon atom;

R<sub>4</sub> and R<sub>5</sub> are independently selected from the group consisting of H, aliphatic substituents, aromatic substituents, RO, RS and (R)<sub>2</sub>N, wherein R is an aliphatic or aryl group;

L is a linker or a single bond; and

each of R<sub>1</sub> and R<sub>2</sub> is independently a metal coordinating group, a non-coordinating organic group, a metal coordinating group derivatized with a biologically active molecule, or a non-coordinating organic group derivatized with a biologically active molecule wherein said solid phase bound organic conjugate is capable of reacting in which the reaction with a solution of [M(H<sub>2</sub>O)<sub>3</sub>(CO)<sub>3</sub>]<sup>n+</sup> can take place.

21. (Currently Amended) The kit [Kit] as claimed in claim 20, wherein the container is a vessel or column.

22. (Currently Amended) The kit **[[Kit]]** as claimed in claim 20, further comprising a solution of  $[M(H_2O)_3(CO)_3]^{n+}$ , wherein M is a metal, and n is 1, 2 or 3.




23. (Currently Amended) The kit **[[Kit]]** as claimed in claim 20, further comprising reagents for preparation of  $[M(H_2O)_3(CO)_3]^{n+}$ , wherein M is a metal, and n is 1, 2 or 3.

24. (Currently Amended) The kit **[[Kit]]** as claimed in claim 20, further comprising a facility for filtration.

25. (Previously Presented) The solid phase bound organic conjugate according to claim 15, wherein the organic conjugate is in contact with a solution of  $[M(H_2O)_3(CO)_3]^{n+}$ , wherein M is selected from the group consisting of technetium (Tc), rhenium (Re), rhodium (Rh), platinum (Pt), iridium (Ir), ruthenium (Ru), and copper (Cu); and n is 1, 2 or 3.

26. (Previously Presented) The solid phase bound organic conjugate according to claim 25, wherein M is  $^{99m}\text{Tc}$  and n is 1.

27. (Currently Amended) The solid phase bound organic conjugate according to claim 15, wherein at least one of  $R_1$  and  $R_2$  is selected from the group consisting of:



wherein  $R_3$  is directly attached to the tertiary amine or is an aliphatic chain containing between 1 and 3 carbons.

28. (Previously Presented) The solid phase bound organic conjugate according to claim 16, wherein the pharmaceutically active small molecule is biotin.

29-31. (Cancelled)

32. (New) The kit according to claim 20, wherein the biologically active molecule is selected from the group consisting of amino acids, steroids, peptides, proteins, carbohydrates, polysaccharides, oligosaccharides, nucleosides, nucleotides, oligonucleotides, polynucleotides, lipids, and pharmaceutically active small molecules.

33. (New) The kit according to claim 32, wherein the pharmaceutically active small molecule is biotin.

34. (New) The kit according to claim 20, wherein the solid phase support is a polyethylene glycol resin or a hybrid of polyethylene glycol and polystyrene.

35. (New) The kit according to claim 22, wherein M is selected from the group consisting of technetium (Tc), rhenium (Re), rhodium (Rh), platinum (Pt), iridium (Ir), ruthenium (Ru), and copper (Cu).

36. (New) The kit according to claim 35, wherein M is  $^{99m}\text{Tc}$  and n is 1.